Xtalpi Inc.’s strategic collaboration with Dovetree Medicines Unus Inc. has made substantial progress, with Xtalpi receiving the second payment under the agreement.
In the treatment of hepatocellular carcinoma (HCC), the long-term benefits of second-line tyrosine kinase inhibitors such as sorafenib are often limited by resistance mechanisms and adverse effects. The deubiquitinase ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1) is upregulated in advanced HCC disease and has been linked to poor prognosis and treatment resistance.
Laverock Therapeutics Ltd. has been awarded two new grants totaling in excess of £2.2 million (US$3 million) to support the next generation of its gene-control platform development, and expansion into additional nononcology therapeutics areas.
Hepatocellular carcinoma (HCC) remains a major cause of cancer death worldwide and, although early-stage disease can sometimes be cured by surgical resection and liver transplantation, advanced cases still respond poorly to current systemic treatments and immunotherapy.
Norroy Bioscience Co. Ltd. has prepared and tested peptide-drug conjugates comprising a fibroblast activation protein α (FAP)-targeting moiety linked to a radionuclide-labeled metal chelating agent for use as positron emission tomography (PET) imaging agents in the diagnosis and/or treatment of cancer.
A University of California patent describes new poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1), DNA repair and serine/threonine-protein kinase ATR inhibitors potentially useful for the treatment of cancer.
Synnovation Therapeutics Inc. has discovered new proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin-protein ligases binding moiety coupled to nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2)-targeting moiety potentially useful for the treatment of cancer.
RSS
